Phase 2 Study of KH903 in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma As Second-Line Therapy

NCT04555304 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

81

Enrollment

INDUSTRY

Sponsor class

Conditions

Gastric Cancer
Gastroesophageal Cancer

Interventions

DRUG: KH903 + Paclitaxel
DRUG: Placebo + Paclitaxel

Sponsor

Chengdu Kanghong Biotech Co., Ltd.